Methods and compositions for modulating prostasin

Abstract

The invention provides methods and compositions related to modulating prostasin.

1 . A method of modulating prostasin activity in a subject, said method comprising administering to the subject an antagonist, whereby prostasin activity is modulated in the subject, wherein the antagonist is an antibody antagonist that disrupts physiological inhibition of prostasin, wherein the antibody antagonist is capable of inhibiting HAI-1/1B inhibition of prostasin activity. 
     
     
         2 . A method of treating a pathological condition associated with downregulation of prostasin in a subject, said method comprising administering to the subject the antagonist, wherein the antagonist is an antibody antagonist that disrupts physiological inhibition of prostasin, wherein the antibody antagonist is capable of inhibiting HAI-1/1B inhibition of prostasin activity, whereby prostasin activity is increased. 
     
     
         3 . (canceled) 
     
     
         4 . A method of reducing physiological inhibition of prostasin activity in a subject having a pathological condition associated with down-regulation of prostasin activity, said method comprising administering to the subject the antagonist, wherein the antagonist is an antibody antagonist that disrupts physiological inhibition of prostasin, wherein the antibody antagonist is capable of inhibiting HAI-1/1B inhibition of prostasin activity, whereby prostasin activity is enhanced. 
     
     
         5 . (canceled) 
     
     
         6 . The method of  claim 2 , wherein the pathological condition associated with downregulation of prostasin is cancer at a stage associated with sub-normal prostasin activity. 
     
     
         7 . The method of  claim 6 , wherein the cancer is high-grade prostate cancer. 
     
     
         8 . The method of  claim 7 , wherein the cancer is hormone-refractory prostate cancer. 
     
     
         9 . The method of  claim 6 , wherein the cancer is invasive prostate cancer. 
     
     
         10 . (canceled) 
     
     
         11 . The method of  claim 2 , wherein the pathological condition associated with downregulation of prostasin is a cancerous tumor comprising a cell that expresses prostasin and/or HAI-1/1B. 
     
     
         12 . The method of  claim 2 , wherein the pathological condition associated with downregulation of prostasin is a cell proliferative disorder associated with dysregulated activity of prostasin and/or HAI-1/1B.